Positive results from phase II long-term safety study evaluating topical roflumilast cream (ARQ-151) as potential once-daily topical treatment for plaque psoriasis

Long-term safety found roflumilast cream 0.3% applied once daily for up to 52 weeks demonstrated favourable safety and tolerability over long-term treatment period, consistent with that seen in phase 2b study, with 3.6% of patients experiencing a treatment-related adverse event.

Source:

Biospace Inc.